The treatment of MTX had no significant effect on the levels of OPG, RANKL/OPG and IL-4 in MTX testing groups compared to those in anti-CD3/CD28 group in RA patients (P > 0.05; Table 3; Figures 5, 6, and 7). The gene discussed is TNFRSF11B; the disease is rheumatoid arthritis.